NCT06121752 2024-10-15
DNET
Asian Institute of Gastroenterology, India
Phase NA Unknown
Clinical Trials
37 trialsNCT05709171 2023-11-22
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Rigshospitalet, Denmark
Phase 2 Unknown
NCT04375267 2023-11-14
LuPARP
Vastra Gotaland Region
Phase 1 Unknown
NCT04897542 2023-09-18
Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT05513469 2023-04-07
Radio-Marker
Erasmus Medical Center
Phase NA Unknown
NCT03478358 2022-08-31
Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
Peking Union Medical College Hospital
Phase 1 Unknown
NCT04525638 2022-08-02
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
Phase 2 Unknown
NCT02817945 2022-04-07
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown
NCT05268952 2022-03-07
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)
University Hospital, Antwerp
Phase NA Unknown
NCT05113355 2021-11-24
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04427787 2021-09-05
LOLA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04790708 2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA Unknown
NCT01744249 2021-02-02
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
Phase 2/3 Unknown
NCT04491851 2020-11-05
Impact of Peptides and Chelators on Somatostatin Receptor Antagonists
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04194125 2020-11-04
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
University of Warmia and Mazury
Phase 2 Unknown
NCT03881306 2020-08-20
DEBOXA for Inoperable NET Liver Metastases
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT03734913 2020-07-22
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04207463 2020-06-17
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04029428 2020-04-01
POLNETS_PRRT
University of Warmia and Mazury
Phase 2 Unknown
NCT00874614 2020-02-20
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Unknown
NCT03422029 2020-02-07
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
Peking University
Phase 2 Unknown
NCT04152928 2019-11-06
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities
Tel-Aviv Sourasky Medical Center
Phase NA Unknown
NCT04154241 2019-11-06
Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor
Tel-Aviv Sourasky Medical Center
Phase NA Unknown
NCT04041882 2019-08-01
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown
NCT03083210 2019-05-20
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Samsung Medical Center
Phase 4 Unknown
NCT03622333 2018-08-20
Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)
CHU de Reims
Phase NA Unknown
NCT03629847 2018-08-14
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
King Faisal Specialist Hospital & Research Center
Phase 1/2 Unknown
NCT03511768 2018-04-30
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT03308682 2017-10-12
177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
Peking Union Medical College Hospital
Phase 1 Unknown
NCT03279601 2017-09-12
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
Peking University
Phase 2 Unknown
NCT01902238 2016-12-01
EUS
Asan Medical Center
Phase NA Unknown
NCT02455596 2016-01-05
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2 Unknown
NCT02279758 2014-10-31
MetNet
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT02246322 2014-09-22
EUS-FNA
Istituto Clinico Humanitas
Phase NA Unknown
NCT02038738 2014-01-17
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Ochsner Health System
Phase 1/2 Unknown
NCT01931488 2013-08-29
124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT01175096 2010-08-04
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Guangdong Provincial People's Hospital
Phase 1/2 Unknown